We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Broccoli Extract Shows Potential as Diabetes Treatment

By LabMedica International staff writers
Posted on 27 Jun 2017
Research carried out with animal models and with an obese human population has shown that a natural constituent of certain types of cruciferous plants has potential for treating type II diabetes.

Investigators at the University of Gothenburg (Sweden) analyzed the pattern of gene expression associated with type II diabetes and compared it to the gene signatures for thousands of drug candidates to find compounds that could counteract the effects of diabetes. More...
The leading candidate from this analysis was sulforaphane, a natural compound found in broccoli and other vegetables.

Sulforaphane is an organosulfur compound that has been found to exhibit anticancer, antidiabetic, and antimicrobial properties in various experimental models. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts, or cabbages. The enzyme myrosinase transforms glucoraphanin, a glucosinolate, into sulforaphane upon damage to the plant (such as from chewing). Young sprouts of broccoli and cauliflower are particularly rich in glucoraphanin.

The investigators reported in the June 14, 2017, online edition of the journal Science Translational Medicine that sulforaphane suppressed glucose production in hepatic cells by nuclear translocation of the protein nuclear factor erythroid 2–related factor 2 (NRF2) and decreased expression of key enzymes in in the glucose synthesis pathway. Moreover, sulforaphane reversed the disease signature in the livers from diabetic animals and attenuated exaggerated glucose production and glucose intolerance by a magnitude similar to that of diabetes drug metformin.

In a clinical trial, sulforaphane-containing broccoli sprout extract was found to be well tolerated and improved fasting glucose in human patients with obesity and dysregulated type II diabetes. The concentrated broccoli sprout extract reduced fasting blood glucose and glycated hemoglobin (HbA1c) levels.

"There are strong indications that this can become a valuable supplement to existing medication," said senior author Dr. Anders Rosengren, docent in metabolic physiology at the University of Gothenburg. "Sulforaphane targets a central mechanism in type II diabetes and has a mild side-effect profile. As functional food, it can reach the patients faster than a medication, and it is also an interesting concept from a diabetes perspective where diet is central."

Related Links:
University of Gothenburg


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.